636 related articles for article (PubMed ID: 14993633)
21. Relapse as histoid leprosy after receiving multidrug therapy (MDT); a report of three cases.
Shaw IN; Ebenezer G; Rao GS; Natrajan MM; Balasundaram B
Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):272-6. PubMed ID: 11221089
[TBL] [Abstract][Full Text] [Related]
22. The efficacy of a four-week, ofloxacin-containing regimen compared with standard WHO-MDT in PB leprosy.
Balagon MF; Cellona RV; Abalos RM; Gelber RH; Saunderson PR
Lepr Rev; 2010 Mar; 81(1):27-33. PubMed ID: 20496567
[TBL] [Abstract][Full Text] [Related]
23. A comparative trial of single dose chemotherapy in paucibacillary leprosy patients with two to three skin lesions.
2-3 Lesion Multicentre Trial Group
Indian J Lepr; 2001; 73(2):131-43. PubMed ID: 11579649
[TBL] [Abstract][Full Text] [Related]
24. A comparative clinico-pathological study of single dose ROM in paucibacillary leprosy patients with 1-3 skin lesions.
Deshmukh AR; Dhurat RS; Jerajani HR
Indian J Lepr; 2003; 75(3):209-17. PubMed ID: 15267190
[TBL] [Abstract][Full Text] [Related]
25. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
Sapkota BR; Shrestha K; Pandey B; Walker SL
Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
[TBL] [Abstract][Full Text] [Related]
26. Single dose 'ROM' therapy--is it really effective?
Mandal AK
Natl Med J India; 1998; 11(5):247. PubMed ID: 10997176
[No Abstract] [Full Text] [Related]
27. Combined chemotherapy trials with regimens containing ofloxacin and rifampicin for multibacillary leprosy patients.
Sampoonachot P; Bundit C; Kuhacharoen N; Peerapakorn S; Kampirapap K; Poomlek A; Bampenyu S; Tiasiri S; Rungruang S; Surasondhi S; Supanwanit S; Wiriyawipart S
J Med Assoc Thai; 1996 Apr; 79(4):210-7. PubMed ID: 8708505
[TBL] [Abstract][Full Text] [Related]
28. Once monthly rifampicin (1200 mg) plus daily dapsone (100 mg) and clofazimine (100 mg) in the initial treatment of lepromatous leprosy.
Chandorkar AG; Burte NP; Gade RK; Bulakh PM
Indian J Lepr; 1984; 56(1):63-70. PubMed ID: 6384381
[TBL] [Abstract][Full Text] [Related]
29. Delayed resolution versus treatment failure in paucibacillary leprosy patients under six months fixed duration multidrug therapy.
Job CK; Jayakumar J; Aschhoff M
Indian J Lepr; 1997; 69(2):131-42. PubMed ID: 9290964
[TBL] [Abstract][Full Text] [Related]
30. Adverse effects from multi-drug therapy in leprosy: a Brazilian study.
Deps PD; Nasser S; Guerra P; Simon M; Birshner Rde C; Rodrigues LC
Lepr Rev; 2007 Sep; 78(3):216-22. PubMed ID: 18035772
[TBL] [Abstract][Full Text] [Related]
31. Adverse effects of alternative therapy (minocycline, ofloxacin, and clofazimine) in multibacillary leprosy patients in a recognized health care unit in Manaus, Amazonas, Brazil.
Maia MV; Cunha Mda G; Cunha CS
An Bras Dermatol; 2013; 88(2):205-10. PubMed ID: 23739719
[TBL] [Abstract][Full Text] [Related]
32. Single dose ROM therapy in Goa.
Shukla P; Miranda MS; Prabhudesai R; Rege VL
Indian J Lepr; 2002; 74(2):169-72. PubMed ID: 12708738
[No Abstract] [Full Text] [Related]
33. [Multi-drug therapy trials for leprosy in Senegal: first observations relative to liver tolerance of multibacillary patients. Therapeutic consequences].
Millan J; Roux G; Loko S; Naudin JC; Boucher P; Bodian M; Camara M; Moreira-Diop T; Grosset J
Acta Leprol; 1986; 4(4):427-44. PubMed ID: 3296613
[TBL] [Abstract][Full Text] [Related]
34. Multidrug therapy (MDT) and leprosy control.
Noordeen SK
Indian J Lepr; 1990; 62(4):448-58. PubMed ID: 2086680
[No Abstract] [Full Text] [Related]
35. 10-12 years follow-up of highly bacillated BL/LL leprosy patients on combined chemotherapy and immunotherapy.
Katoch K; Katoch VM; Natrajan M; Sreevatsa ; Gupta UD; Sharma VD; Shivanavar CT
Vaccine; 2004 Sep; 22(27-28):3649-57. PubMed ID: 15315844
[TBL] [Abstract][Full Text] [Related]
36. Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.
Cruz RCDS; Bührer-Sékula S; Penna GO; Moraes MEA; Gonçalves HS; Stefani MMA; Penna MLF; Pontes MAA; Talhari S
An Bras Dermatol; 2018 Jun; 93(3):377-384. PubMed ID: 29924240
[TBL] [Abstract][Full Text] [Related]
37. Follow up of BL/LL patients on a slightly modified WHO regimen of multidrug therapy.
Katoch K; Ramu G; Ramanathan U; Sengupta U; Sreevatsa
Indian J Lepr; 1987; 59(1):36-43. PubMed ID: 3611859
[TBL] [Abstract][Full Text] [Related]
38. Clinical, bacteriological and histopathological study of 62 referral relapse cases between Jan 2004 and Dec 2009 at the Foundation for Medical Research, Mumbai.
Shetty VP; Wakade AV; Ghate SD; Pai VV
Lepr Rev; 2011 Sep; 82(3):235-43. PubMed ID: 22125931
[TBL] [Abstract][Full Text] [Related]
39. Single-dose treatment for paucibacillary leprosy; clinical problems and management.
Pai VV; Bulchand HO; Revankar CR; Ganapati R
Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):310-2. PubMed ID: 10575414
[No Abstract] [Full Text] [Related]
40. Is there a role for rifampicin, ofloxacin and minocycline (ROM) therapy in the treatment of leprosy? Systematic review and meta-analysis.
Setia MS; Shinde SS; Jerajani HR; Boivin JF
Trop Med Int Health; 2011 Dec; 16(12):1541-51. PubMed ID: 21914093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
